Screenshot 2022-05-02 at 06.39.21.png

Multicenter
study (MCS) office

Screenshot 2022-07-07 at 02.51.48.png
ClinicalTrials.gov Identifier: NCT05496517

Ovarian cancer (OC) is one of the most common types of malignant tumors and the eighth cause of cancer-related mortality in women. FIGO staging is considered the standard classification system that determines prognosis and management of newly diagnosed OC. However, there are numerous gaps in this staging system that would limit interpretation of clinically relevant data.

Management of ovarian cancer is surgical and comprises bilateral sapling-oophorectomy, total abdominal hysterectomy , and infracolic omentectomy. Additional surgical steps and neoadjuvant therapy are potentially determined by disease characteristics. Extent of surgery and neoadjuvant treatment is directly related to postoperative comorbidities and contributes to long term prognosis. Therefore, development of an individualized prognostic and decision-making system, based on large multicenter studies, would facilitate accurate prediction of disease prognosis and determination of individualized management strategy.

This project aims at creating an individualized prognostic model using patient

characteristics and disease features to determine disease prognosis using machine

learning technology.

The model can be used to determine the optimal management plan per patient in priori and highlight risk and timing of disease recurrence.

The study will comprise at least 8 international cancer centers. Data of patients,

newly diagnosed with OC between January 2010 and December 2016, will be

retrospectively collected. Therefore, a follow-up of at least 5 years would be granted. All women who will be diagnosed with primary ovarian cancer at any stage, of all histological types and grades eligible for the study. All contributing centers should acquire institutional review board (IRB) approval prior to data collection.

Inclusion criteria:

• Women diagnosed with ovarian cancer between January 2010 and December 2016.

• Primary non-recurrent diagnosis of ovarian cancer.

• Women should be diagnosed and managed by the corresponding center.

• Patients with adequate clinical and pathological data

 

Exclusion criteria:

• Inadequate information and follow-up for at least 5 years.

• Authorization to use anonymous patient data for research purposes.

Data will be collected using an excel spreadsheet designed for this study and shared

Primary outcome of the study will be cancer-specific survival (CSS) rate at 3 and 5

years after initiation of treatment. Recurrence-free survival (RFS) rate at 3 and 5 years constitutes the secondary outcome

  • Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.

  • Caan BJ, Thomson CA. Breast and ovarian cancer. Optim Women’s Heal through Nutr. Published online 2007:229-263. doi:10.1369/0022155411428469

  • Urban N. Early detection of ovarian cancer: Methodological considerations. Int J Gynecol Obstet. 2000;70:D9-D9

  • Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3(4):355-366

  • 5. Goff BA, Mandel LS, Melancon CH, Muntz HG. 50. Goff 2004.pdf. 2015;291(22):2705-2712.

  • Jordan SJ, Green AC, Whiteman DC, Webb PM. Risk factors for benign, borderline and invasive mucinous ovarian tumors: Epidemiological evidence of a neoplastic continuum? Gynecol Oncol. 2007;107(2):223-230

  • Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 2019;11:287-299

  • Salvo G, Odetto D, Pareja R, Frumovitz M, Ramirez PT. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. Int J Gynecol Cancer. 2020;30(6):873-878. doi:10.1136/ijgc-2020-001257

  • Wright JD, Matsuo K, Huang Y, et al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019;134(1):49-57

  • McCorkle, R., et al. (2003). "The silent killer: psychological issues in ovarian cancer." Holistic nursing practice 17(6): 300-308.